The Michael J. Fox Foundation for Parkinson's Research
  Research
  News & Events
  Funding Programs
  About

PD Online Research

Alzheimer Research Forum
  Current Papers
  ARF Recommends
  Research News
PDGene - Gene overview of all published PD-association studies for PARK2
Back Search Methods Disclaimer Credits
 Gene: PARK2  (PDJ; PRKN; AR-JP; LPRS2)  Entrez Gene
 Protein: PARK2 Parkinson disease (autosomal recessive, juvenile) 2  (parkin; E3 ubiquitin ligase)  ProteinLink
 Chromosome: 6   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 27 November 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      PD Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Brooks, 2009
Overlaps with
Simon-Sanchez, 2009 (USA)
CL  7  (detail)  250
(39%)
C41
(7-50)
54
(-)
276
(72%)
39
(15-53)
n.a.
Chen, 2003
USA CL  4  (detail)  27
(37%)
U36.7
(24-49)
-50
(-)
-Negative
Chung, 2010
USA CL  32  (detail)  449
(35%)
-64.7
(23-88)
70.3
(44-90)
449
(35%)
71.8
(45-93)
Trend
Clark, 2006
USA CL  8  (detail)  101
(41%)
C41.1 + 7.2
(-)
53 + 9.8
(-)
105
(44%)
60.6 + 10.6
(-)
Negative
Eerola, 2002
Finland CL  3  (detail)  147
(41%)
C-67.2
(38-88)
137
(64%)
65.8
(37-87)
Negative
Fung, 2006
Overlaps with
Simon-Sanchez, 2009 (USA)
CL  2  (detail)  267
(-)
C--270
(-)
68
(55-88)
n.a.
Kay, 2006
USA (I) CL  13  (detail)  302
(38%)
C56.7 + 13
(7-82)
67.8 + 10.6
(36-87)
301
(53%)
67 + 11.7
(32-88)
Negative
Kay, 2006
USA (II) CL  1  (detail)  1260
(31%)
C58.2 + 11.9
(15-90)
67.9 + 10.6
(30-93)
1657
(65%)
67.3 + 20.3
(20-109)
Negative
Klein, 2000
Germany & Italy CL  3  (detail)  100
(51%)
C57.1 + 12.1
(-)
63.1 + 12.5
(-)
100
(42%)
-Positive
Koziorowski, 2009
Poland CL  3  (detail)  79
(42%)
C34.9 + 4.8
(20-40)
-204
(62%)
30.4 + 10.9
(-)
Negative
Lesage, 2007
France CL  3  (detail)  172
(42%)
C36.8 + 9.3
(6-58)
49.6 + 11.8
(16-75)
170
(45%)
62.9 + 9.6
(27-84)
Positive
Lincoln, 2003
Overlaps with
Chung, 2010 (USA)
CL,PO  3  (detail)  319
(38%)
C64
(31-85)
70
(33-99)
195
(62%)
72
(37-94)
Negative
Lucking, 2003
Europe CL  3  (detail)  194
(42%)
C53.1 + 12.7
(25-81)
-125
(40%)
53.6 + 14
(18-81)
Positive
Mata, 2002
Spain CL  4  (detail)  105
(-)
C--150
(-)
50 + 10
(-)
Negative
Mellick, 2001
Australia CL  1  (detail)  236
(41%)
C59.6
(-)
67.9
(-)
234
(43%)
68.9 + 11.9
(-)
Positive
Oliveri, 2001
Italy CL  4  (detail)  118
(45%)
C60.7
(-)
66.8
(-)
100
(48%)
68.8 + 9.1
(-)
Negative
Pankratz, 2008
USA (PROGENI, GenePD) CL  35  (detail)  857
(41%)
C61.9 + 10.8
(-)
-867
(60%)
54.8 + 13.1
(-)
Negative
Poorkaj, 2004
Overlaps with
Kay, 2006
CL  8  (detail)  39
(44%)
C32.6 + 8.1
(7-40)
52.5 + 9.9
(36-81)
96
(-)
37.9 + 12.1
(18-72)
n.a.
Schlitter, 2006
Germany CL  1  (detail)  95
(-)
C55.2
(-)
-149
(-)
43
(19-69)
Negative
Schlitter, 2006
Norway CL  1  (detail)  96
(-)
C63.6
(-)
-112
(-)
-Negative
Simon-Sanchez, 2007
GWAS meta-analysis CL  1  (detail)  267
(-)
C--270
(-)
68
(55-88)
Negative
Simon-Sanchez, 2009
USA, Germany (GWAS) CL,PO  12  (detail)  1745
(45%)
C55.8
(7-98)
-4047
(50%)
-Trend
Simon-Sanchez, 2009
USA, Germany, UK (Stage II) CL,PO  1  (detail)  3452
(32%)
M61.1
(-)
-4756
(39%)
-Negative
Simon-Sanchez, 2009
USA (NINDS-GWAS) CL  23  (detail)  931
(40%)
C--790
(58%)
-Trend
Simon-Sanchez, 2011
Netherlands (GWAS) CL,PO  1  (detail)  772
(36%)
U55.3
(16-84)
62.3
(29-89)
2024
(56%)
53.7
(45-95)
Negative
Sutherland, 2009
Australia CL  4  (detail)  331
(51%)
C60.1 + 10.6
(-)
70.3 + 8.7
(-)
296
(51%)
70.5 + 8.9
(-)
Negative
West, 2002
USA CL  1  (detail)  319
(-)
C--196
(-)
-Positive
 African Descent
Okubadejo, 2008
Nigeria CL  6  (detail)  57
(25%)
C58.2 + 9.1
(40-75)
62.3 + 9.1
(43-80)
51
(31%)
63.7 + 8.7
(42-87)
Negative
 Asian
Hu, 2000
Taiwan CL  3  (detail)  92
(47%)
C-68.2
(52-90)
98
(-)
75.1
(65-81)
Negative
Mizuta, 2006
Japan CL  3  (detail)  190
(-)
C--190
(-)
-Negative
Peng, 2003
China CL  1  (detail)  116
(35%)
C56.3 + 10.7
(21-80)
-124
(36%)
57.2 + 9.4
(31-79)
Positive
Satoh, 1999
Japan CL  1  (detail)  71
(61%)
C-68.8 + 3.8
(46-86)
109
(55%)
65.7
(40-88)
Positive
Wang, 1999
Japan CL  3  (detail)  160
(-)
C55.4 + 10.7
(-)
-160
(-)
-Positive
 Other/Mixed
Aguiar, 2008
Brazil CL  2  (detail)  72
(32%)
C36.4 + 8.9
(9-50)
45.6 + 10.5
(13-77)
81
(30%)
38.4 + 12.5
(-)
Positive
Biswas, 2006
India CL  4  (detail)  138
(-)
C47 + 14
(5-77)
-100
(-)
55 + 10
(-)
Negative
Biswas, 2007
India CL  2  (detail)  138
(-)
C47 + 14
(-)
-141
(-)
55 + 10
(-)
Positive
Clark, 2006
USA CL  1  (detail)  14
(-)
C--90
(-)
-Negative
Haylett, 2011
South Africa CL  6  (detail)  229
(-)
C54.4 + 12.1
(17-80)
---Negative
Martinez, 2009
Mexico CL  4  (detail)  117
(41%)
C59 + 12
(25-83)
-122
(48%)
50 + 15
(25-85)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Chung, 2010
USA  32  (detail)   654
(36%)
C60.4
(28-87)
66.3 + 30.8
(-)
654
(50%)
65.1
(32-90)
Trend
Maraganore, 2005
USA  1  (detail)  443443
(39%)
C61
(31-94)
68
(33-96)
443
(52%)
66
(29-90)
Negative
Oliveira, 2003a
Overlaps with
Oliveira, 2003b
 4  (detail)  307363
(-)
C--50
(-)
-n.a.
Oliveira, 2003b
USA  6  (detail)  397607
(41%)
C62 + 13
(17-90)
-872
(55%)
67 + 12
(27-96)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis ->  "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
PDGene Recent Updates
PDGene Top Results
PDGene Stats
Studies: 881
Genes: 915
Polymorphisms: 3446
Meta-analyses: 889
PDGene Links
GEO-PD Meeting 2012
PDmutDB
Curated by the VIB Department of Molecular Genetics of the University of Antwerp
Parkinson's disease Mutation Database
Curated by Parkinson's Institute from Leiden University Medical Center
Mutation Database for Parkinson's Disease
Curated by the Institute for Infocomm Research in Singapore
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.
PD Online Research
Alzheimer Research Forum
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2014 Biomedical Research Forum LLC Disclaimer Copyright